Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.
With a budget potentially exceeding EUR 47.1bn (DKK 350bn), the EU Commission wants to establish a new agency to ward against future health crises. While the financial makeup is uncertain, good news for future clinical trials might be on the way.
That millions of people have not been able to get their hearing aids adjusted due to the pandemic has caused a huge backlog, and according to Demant CEO Søren Nielsen, this will impact the industry for some time.
In December last year, Sonova dished out almost EUR 5m to Sensorion, a French biotech company specialized in the treatment of hearing disorders. Now, the two companies are entering into a strategic partnership with the goal of improving diagnostics and treatment through genetic analysis.
The Lancet has published new data on Johnson & Johnson and Bavarian Nordic's combined vaccine against Ebola, which according to the US life science group strongly supports preventatitve use of the vaccine.
A lack of short-term catalysts is one of the reasons that investment bank Jefferies has changed its recommendation for Genmab stock. The biotech company's share price increase since the start of the year is another reason, as S&P's biotech index has fallen during the same period.
Leo Pharma partner Pellepharm's drug patidegib has not generated sufficiently convincing phase III data for the dermatology group to utilize its acquisition option and take over the candidate – and the company.
While Novo Nordisk struggles to meet the demand for its injection-based treatment Wegovy in the US, the pharmaceutical company has started a phase IIIa trial of semaglutide as a tablet-based treatment for obesity, aiming for similar weight loss results.
Hearing aid manufacturer WS Audiology has invested in the sustainable conversion of its Singapore headquarters and facility. The company, which is the third-biggest in the industry, is now well on its way towards the goal of running on 100 percent renewable energy by 2025.
IO Biotech joins forces with partner MSD in the development of a new therapy for the treatment of skin cancer in combination with IO Biotech's lead candidate Keytruda. A big phase III trial now commences, and if successful, IO Biotech maintains commercial rights.